Alnylam can develop global liver cancer RNAi on PhII data from China deal with Ascletis
This article was originally published in Scrip
Alnylam Pharmaceuticals lined up Ascletis Pharmaceuticals in China to develop ALN-VSP for liver cancers, including hepatocellular carcinoma (HCC). This is the first new partner for one of Alnylam's RNA interference programmes since the company announced a corporate restructuring that relied on collaborations to advance the company's RNAi therapeutics.
You may also be interested in...
Generic OTC paracetamol and ibuprofen pack prices are gradually returning to pre-COVID levels, according to market analysts Wavedata. But a second wave could drive prices back up again.
As one of the leading players in the US, albeit with a declining core business, Sandoz is naturally watching developments from the Federal Circuit’s precedential ruling on induced infringement for carved out indications. Management discussed the topic as Sandoz reported third-quarter financials.
With the India business on the road to recovery and the US growth outlook muted, Torrent hopes to keep the boat steady in fiscal 2021. It also expects an order in Q3 in a patent infringement case pertaining to AstraZeneca’s Farxiga, where it and multiple Indian firms are seeking to launch generic versions.